Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orvepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orvepitant SCHEMBL21931158 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL2483270 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL1421784 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL29373789 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL2484579 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL19581227 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL23895405 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL19117640 | 1.00 | TACR1 (1.00) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL5360752 | 0.99 | TACR1 (0.99) | TACR1SIGMAR1PTAFRCYP3A4 | |
| Orvepitant SCHEMBL30110395 | 0.99 | TACR1 (0.99) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297152-B1 | ANHYDROUS CRYSTAL FORM OF ORVEPITANT MALEATE | NERRE THERAPEUTICS LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| US-8309553-B2 | Anhydrous crystal form of ovrepitant maleate | GLAXO GROUP LIMITED (GB) | 2012-11-13 | — | — | US | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110166150-A1 | Anhydrous Crystal Form Of Ovrepitant Maleate | GLAXO GROUP LIMITED | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166150-A1 | Anhydrous Crystal Form Of Ovrepitant Maleate | OR10J3, AVPR2, AVPR1A | TACR1 40/4885SIGMAR1 75/4885PTAFR 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.